ETPrime

Sandu Pharmaceuticals Share Price

  • 50.000.04 (0.08%)
  • Volume: 535
BSE
  • Closed
  • Last Updated On: 20 Jun, 2025, 03:53 PM IST
STOCK SCORE
ETPrime Only
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Sandu Pharmaceuticals Share Price
  • 50.000.04 (0.08%)
  • Volume: 535
Advertisment

Sandu Pharma share price insights

View All

  • Company witnessed QoQ revenue decline of 23.15%, which is lowest in the last 3 years. (Source: Standalone Financials)

  • Sales de-grew by 0.51%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Standalone Financials)

  • Company has spent less than 1% of its operating revenues towards interest expenses and 16.25% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

  • Sandu Pharmaceuticals Ltd. share price moved up by 0.08% from its previous close of Rs 49.96. Sandu Pharmaceuticals Ltd. stock last traded price is 50.00

    Share PriceValue
    Today/Current/Last-50.00
    Previous Day-49.96

InsightsSandu Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		31.13
    EPS - TTM
    (₹)    		1.61
    MCap
    (₹ Cr.)    		48.30
    Sectoral MCap Rank
    		145
    PB Ratio
    (x)    		1.15
    Div Yield
    (%)    		1.60
    Face Value
    (₹)    		10.00
    Beta

    Beta

    1 Month4.35
    3 Months2.52
    6 Months1.30
    1 Year1.01
    3 Years0.97

    		4.35
    VWAP
    (₹)    		50.40
    52W H/L
    (₹)
    69.50 / 43.75

    Sandu Pharma Share Price Returns

    1 Day0.08%
    1 Week-3.83%
    1 Month-10.89%
    3 Months-2.86%
    1 Year-15.57%
    3 Years-18.43%
    5 Years186.53%

    ET Stock ScreenersTop Score Companies

    Check whether Sandu Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Sandu Pharma News & Analysis

    View all Sandu Pharma Share News & Announcements

    Sandu Pharma Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    Sandu Pharma Share Recommendations

    No Recommendations details available for this stock.
    Check out other stock recos.

    Sandu Pharma Financials

    • Insights

      • Quarterly Topline Performance

        Company witnessed QoQ revenue decline of 23.15%, which is lowest in the last 3 years. (Source: Standalone Financials)

      • Topline Contraction

        Sales de-grew by 0.51%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Standalone Financials)
      Quarterly | AnnualMar 2025Dec 2024Sep 2024Jun 2024Mar 2024
      Total Income14.1418.4017.7317.0915.91
      Total Income Growth (%)-23.153.743.767.44-8.87
      Total Expenses13.7717.5616.9716.8015.18
      Total Expenses Growth (%)-21.593.501.0110.66-11.02
      EBIT0.370.840.770.290.73
      EBIT Growth (%)-55.869.23162.14-59.8383.80
      Profit after Tax (PAT)0.330.560.500.170.59
      PAT Growth (%)-42.0113.73197.06-71.97188.13
      EBIT Margin (%)2.614.544.311.714.57
      Net Profit Margin (%)2.313.062.790.983.74
      Basic EPS (₹)0.340.581.950.170.62
      Quarterly | AnnualMar 2025Dec 2024Sep 2024Jun 2024Mar 2024
      Total Income14.1418.4017.7317.0915.90
      Total Income Growth (%)-23.153.743.767.46-8.89
      Total Expenses13.7717.5716.9616.8015.18
      Total Expenses Growth (%)-21.643.600.9710.66-11.02
      EBIT0.370.830.770.290.72
      EBIT Growth (%)-55.366.97164.15-59.6683.02
      Profit after Tax (PAT)0.330.560.500.170.59
      PAT Growth (%)-41.2411.08199.82-71.85186.36
      EBIT Margin (%)2.614.494.351.714.56
      Net Profit Margin (%)2.313.022.820.983.73
      Basic EPS (₹)0.340.570.520.170.50
      Quarterly | Annual FY 2025 FY 2024
      Total Revenue67.3667.70
      Total Revenue Growth (%)-0.513.09
      Total Expenses65.2065.63
      Total Expenses Growth (%)-0.663.42
      Profit after Tax (PAT)1.551.46
      PAT Growth (%)6.19-3.90
      Operating Profit Margin (%)3.363.17
      Net Profit Margin (%)2.302.17
      Basic EPS (₹)1.601.51
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue67.3667.7065.6865.5858.95
      Total Revenue Growth (%)-0.513.080.1411.2520.75
      Total Expenses65.2065.6363.4663.2757.27
      Total Expenses Growth (%)-0.653.430.3010.4719.56
      Profit after Tax (PAT)1.551.461.521.591.09
      PAT Growth (%)6.05-4.15-4.1245.4851.67
      Operating Profit Margin (%)3.363.173.513.703.05
      Net Profit Margin (%)2.302.172.332.421.85
      Basic EPS (₹)1.601.511.621.991.54

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024
      Total Assets55.7252.41
      Total Assets Growth (%)6.30-3.23
      Total Liabilities13.7011.82
      Total Liabilities Growth (%)15.90-20.79
      Total Equity42.0240.59
      Total Equity Growth (%)3.513.44
      Current Ratio (x)2.182.10
      Total Debt to Equity (x)0.010.00
      Contingent Liabilities0.00-
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets55.7252.4254.1749.2846.96
      Total Assets Growth (%)6.30-3.239.924.9413.40
      Total Liabilities13.7011.8214.9212.8113.47
      Total Liabilities Growth (%)15.91-20.7816.47-4.9010.59
      Total Equity42.0240.6039.2436.4733.49
      Total Equity Growth (%)3.503.477.608.9014.53
      Current Ratio (x)2.182.101.841.992.44
      Total Debt to Equity (x)0.000.000.000.000.00
      Contingent Liabilities0.00---2.83

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Cash from Operations vs PAT

        Operating cash flow of Rs 0.95 cr is 0.61 times compared to the reported net profit of Rs 1.55 cr. (Source: Consolidated Financials)

      • Decrease in Cash from Investing

        Company has used Rs 0.19 cr for investing activities which is an YoY decrease of 85.75%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024
      Net Cash flow from Operating Activities0.950.76
      Net Cash used in Investing Activities-0.19-1.31
      Net Cash flow from Financing Activities-0.46-0.72
      Net Cash Flow0.30-1.27
      Closing Cash & Cash Equivalent1.301.00
      Closing Cash & Cash Equivalent Growth (%)29.86-55.87
      Total Debt/ CFO (x)0.500.00
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities0.950.760.220.957.59
      Net Cash used in Investing Activities-0.18-1.310.53-5.47-5.58
      Net Cash flow from Financing Activities-0.46-0.720.580.931.30
      Net Cash Flow0.31-1.271.33-3.593.31
      Closing Cash & Cash Equivalent1.301.002.270.944.53
      Closing Cash & Cash Equivalent Growth (%)30.98-56.06141.37-79.27193.69
      Total Debt/ CFO (x)0.060.000.000.000.00

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024
      Return on Equity (%)3.693.59
      Return on Capital Employed (%)5.185.11
      Return on Assets (%)2.782.78
      Interest Coverage Ratio (x)28.3943.10
      Asset Turnover Ratio (x)1.241.26
      Price to Earnings (x)30.5838.02
      Price to Book (x)1.131.37
      EV/EBITDA (x)15.4019.95
      EBITDA Margin (%)4.364.04
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)3.683.593.884.353.26
      Return on Capital Employed (%)5.175.115.706.485.21
      Return on Assets (%)2.772.782.813.222.32
      Interest Coverage Ratio (x)28.3643.0835.3826.8820.47
      Asset Turnover Ratio (x)1.241.261.261.361.33
      Price to Earnings (x)30.5838.0233.1139.0623.20
      Price to Book (x)1.131.371.291.700.76
      EV/EBITDA (x)15.2719.9517.0919.555.81
      EBITDA Margin (%)4.364.044.304.514.00

    Financial InsightsSandu Pharma

    • Income (P&L)
    • Cash Flow

      • Quarterly Topline Performance

        Company witnessed QoQ revenue decline of 23.15%, which is lowest in the last 3 years. (Source: Standalone Financials)

      • Topline Contraction

        Sales de-grew by 0.51%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Standalone Financials)

      • Cash from Operations vs PAT

        Operating cash flow of Rs 0.95 cr is 0.61 times compared to the reported net profit of Rs 1.55 cr. (Source: Consolidated Financials)

      • Decrease in Cash from Investing

        Company has used Rs 0.19 cr for investing activities which is an YoY decrease of 85.75%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Sandu Pharma Technicals

    • Stock doesn't have any Buy/Sell Signals.

    • Price Analysis Data details are not available.

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic-------

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR---

    Sandu Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Sandu Pharma31.131.153.695.182.780.893.362.301.602.180.010.50
          Fervent Syn31.111.896.076.056.05254.999.089.090.681,166.310.000.00
          Vista Pharma-14.161.45-10.23-9.02-7.71163.16-42.93-46.14-0.791.190.16-1.06
          Medi-Caps Ltd-93.940.44-0.47-0.66-0.45-26.53-3.20-2.24-0.4617.250.000.00
          Transchem Ltd8.920.596.588.896.5518.58268.51198.674.27257.860.000.00
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Roopa Ind
          • Gujarat Terce
          • Veerhealth Care
          • Concord Drugs
          • Bacil Pharma

          Choose from Stocks

            See All Parameters

          Peers InsightsSandu Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Sandu Pharma Shareholding Pattern

            • Loading...
              Showing Sandu Pharma Shareholding as on Mar 2025
              CategoryMar 2025Dec 2024Sep 2024Jun 2024
              Promoters42.9042.9042.9042.90
              Pledge0.000.000.000.00
              FII0.000.000.000.00
              DII0.000.000.000.00
              Mutual Funds0.000.000.000.00
              Others57.1057.1057.1057.10
            • Showing Shareholding as on Mar 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters41,44,73042.90 %0.00
              Pledge00.00 %0.00
              Others55,16,26057.10 %0.00

            Sandu Pharma MF Ownership

            MF Ownership details are not available.

            Top Searches:
            Sandu Pharma News Sandu Pharma Quarterly Results Sandu Pharma Dividend Sandu Pharma Q1 ResultsSandu Pharma Q2 ResultsSandu Pharma Q3 ResultsSandu Pharma Q4 Results

            Sandu Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              May 28, 2025May 19, 2025Board MeetingAudited Results & Final Dividend
              Feb 13, 2025Feb 04, 2025Board MeetingQuarterly Results
              Nov 14, 2024Nov 04, 2024Board MeetingQuarterly Results
              Sep 30, 2024Aug 14, 2024AGMRs.0.8000 per share(8%)Final Dividend & A.G.M.
              Aug 12, 2024Aug 05, 2024Board MeetingQuarterly Results & Final Dividend
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Final8%0.8Sep 19, 2024Aug 14, 2024
              Final7%0.75Sep 18, 2023Aug 14, 2023
              Final7%0.75Sep 23, 2022Aug 12, 2022
              Final5%0.5Sep 22, 2021Aug 16, 2021
              Final8%0.8-May 28, 2025

            • No other corporate actions details are available.

            About Sandu Pharma

            Sandu Pharmaceuticals Ltd., incorporated in the year 1985, is a Small Cap company (having a market cap of Rs 48.30 Crore) operating in Pharmaceuticals sector. Sandu Pharmaceuticals Ltd. key Products/Revenue Segments include Ayurvedic Products for the year ending 31-Mar-2024. Show More

            • Executives

            • Auditors

            • UB

              Umesh B Sandu

              Executive Director
              SB

              Shashank B Sandu

              Non Exe.Non Ind.Director
              SP

              Shubhada P Sandu

              Non Exe.Non Ind.Director
              AR

              Ajit R Kantak

              Ind. Non-Executive Director
              Show More
            • Dileep and Prithvi

            Industry

            Pharma - Indian

            Key Indices Listed on

            -

            Address

            Plot, No. 25, 26, 29 & 30,Pilerne Industrial Estate,Marra, Bardez,Goa, Goa - 403511

            Contact

            [email protected]

            http://www.sandu.in

            More Details

            FAQs about Sandu Pharma share

            • 1. What's the Sandu Pharma share price today?
              Sandu Pharma share price is Rs 50.00 as on 20 Jun, 2025, 03:53 PM IST. Sandu Pharma share price is up by 0.08% based on previous share price of Rs 49.75. Sandu Pharma share price trend:
              • Last 1 Month: Sandu Pharma share price moved down by 10.89%
              • Last 3 Months: Sandu Pharma share price moved down by 2.86%
              • Last 12 Months: Sandu Pharma share price moved down 15.57%
              • Last 3 Years: Sandu Pharma Share price moved down by 18.43%
            • 2. What is 52 week high/low of Sandu Pharma share price?
              Sandu Pharma share price saw a 52 week high of Rs 69.50 and 52 week low of Rs 43.75.
            • 3. What's the market capitalization of Sandu Pharma?
              Market Capitalization of Sandu Pharma stock is Rs 48.30 Cr.
            • 4. What is the PE & PB ratio of Sandu Pharma?
              The PE ratio of Sandu Pharma stands at 31.1, while the PB ratio is 1.15.
            • 5. What are the returns for Sandu Pharma share?
              Return Performance of Sandu Pharma Shares:
              • 1 Week: Sandu Pharma share price moved down by 3.83%
              • 1 Month: Sandu Pharma share price moved down by 10.89%
              • 3 Month: Sandu Pharma share price moved down by 2.86%
              • 6 Month: Sandu Pharma share price moved down by 11.33%

            Trending in Markets

            Top Gainers As on 03:59 PM | 20 Jun 2025

            GRSE3,287.60
            309.30 (10.39%)
            BEML4,639.50
            432.90 (10.29%)
            ABB Power18,684.00
            1650.00 (9.69%)
            Swiggy389.50
            33.40 (9.38%)
            MCX India8,085.00
            574.00 (7.64%)

            Top Losers As on 03:59 PM | 20 Jun 2025

            Tata Teleservices63.62
            -13.28 (-17.27%)
            Hindustan Zinc438.60
            -78.65 (-15.21%)
            AstraZeneca8,871.00
            -1324.00 (-12.99%)
            International Gemmol345.95
            -45.05 (-11.52%)
            Concord Biotech Ltd.1,837.30
            -226.30 (-10.97%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Sandu Pharma Share Price
            The Economic Times
            BrowseCompanies:
            OSZAR »